Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

Hungria, Vania T. M. ^{[1
]}

Weisel, Katja ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Mikala, Gabor ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Maiolino, Angelo ^{[9
]}

Pappa, Vasiliki ^{[10
]}

Chraniuk, Dominik ^{[11
]}

Osipov, Iurii ^{[12
]}

Leleu, Xavier ^{[13
]}

Low, Michael ^{[14
]}

Kouri, Fotini ^{[15
]}

Liboon, John ^{[16
]}

Brawley, Chris ^{[17
]}

Lewis, Eric ^{[18
]}

Tubel, Gabriela

Li, Mary ^{[18
]}

McKeown, Astrid

Roy-Ghanta, Sumita ^{[18
]}

Opalinska, Joanna ^{[18
]}

Dimopoulos, Meletios ^{[19
]}

机构：

[1] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp St Ivan Rilski EAD, Dept Clin Hematol, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[9] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[10] Univ Gen Hosp Attikon, Hematol Unit, Dept Internal Med & Res Unit 2, Athens, Greece

[11] Wojewodzki Szpital Zespolony, Dept Hematol, Torun, Poland

[12] VA Almazov Natl Med Res Ctr, St Petersburg, Russia

[13] CHU Poitiers, PRC, Hematol, Poitiers, France

[14] Clayton Univ, Monash Univ, Monash Hlth, Monash Haematol, Clayton, Vic, Australia

[15] GSK, Stevenage, Herts, England

[16] GSK, San Diego, CA USA

[17] GSK, London, England

[18] GSK, Upper Providence, PA USA

[19] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-395

引用

页码：S261 / S262

页数：2

共 50 条

[31] Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study [J].

Eliason, Laurie ;

Correll, Julia ;

Martin, Mona ;

Cardellino, Anna ;

Opalinska, Joanna ;

Piontek, Trisha ;

Gorsh, Boris ;

Sapra, Sandhya ;

Popat, Rakesh .

BLOOD, 2020, 136

[32] Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3 [J].

Leypoldt, L. ;

Callander, N. S. ;

Richardson, P. G. ;

Hus, M. ;

Ribrag, V. ;

Lopez, J. M. ;

Kim, K. ;

Lee, J. H. ;

Dimopoulos, M. A. ;

Schjesvold, F. ;

Facon, T. ;

Jo, J. -C. ;

Min, C. -K. ;

Mielnik, M. ;

Cheng, S. ;

Smith, L. M. ;

Breitbach, C. J. ;

Brawley, C. ;

Sembhi, H. ;

LaMacchia, J. ;

Grosicki, S. .

ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 :176-177

[33] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) [J].

Dimopoulos, Meletios A. ;

Terpos, Evangelos ;

Boccadoro, Mario ;

Delimpasi, Sosana ;

Beksac, Meral ;

Katodritou, Eirini ;

Moreau, Philippe ;

Baldini, Luca ;

Symeonidis, Argiris ;

Bila, Jelena ;

Oriol, Albert ;

Mateos, Maria-Victoria ;

Einsele, Hermann ;

Orfanidis, Ioannis ;

Ahmadi, Tahamtan ;

Ukropec, Jon ;

Kampfenkel, Tobias ;

Schecter, Jordan ;

Qiu, Yanping ;

Amin, Himal ;

Vermeulen, Jessica ;

Carson, Robin ;

Sonneveld, Pieter .

BLOOD, 2020, 136

[34] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) [J].

Nooka, Ajay ;

Lee, Hans C. ;

Badros, Ashraf Z. ;

Voorhees, Peter ;

Hultcrantz, Malin ;

Karlin, Lionel ;

Arnulf, Bertrand ;

Richardson, Paul G. ;

Zhi, Eric ;

Baron, January ;

Piontek, Trisha ;

Lewis, Eric ;

Opalinska, Joanna ;

Gupta, Ira ;

Cohen, Adam D. ;

Lonial, Sagar .

BLOOD, 2020, 136

[35] Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3 [J].

Ferron-Brady, Geraldine ;

Taylor, Adekemi ;

Kaullen, Josh ;

Polireddy, Kishore ;

McKeown, Astrid ;

Sule, Neal ;

Struemper, Herbert .

BLOOD, 2023, 142

[36] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma [J].

Rifkin, Robert ;

Boyd, Kevin ;

Grosicki, Sebastian ;

Kim, Kihyun ;

Di Raimondo, Francesco ;

Dimopoulos, Meletios ;

Weisel, Katja ;

Arnulf, Bertrand ;

Hajek, Roman ;

Hungria, Vania ;

Spencer, Andrew ;

Davis, Randy ;

Riccio, Antonio ;

Kim, Chanbin ;

Wilkes, Jodie ;

Rutledge, Ruth ;

Talekar, Mala ;

Kremer, Brandon E. ;

Gupta, Ira ;

Mateos Manteca, Maria Victoria .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 :172-173

[37] Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis [J].

Quach, Hang ;

Gironella, Mercedes ;

Lee, Cindy ;

Popat, Rakesh ;

Cannell, Paul ;

Kasinathan, Ravi S. ;

Chopra, Bikramjit ;

Rogers, Rachel ;

Ferron-Brady, Geraldine ;

Shafi-Harji, Seema ;

Patel, Nashita ;

Opalinska, Joanna ;

Gupta, Ira ;

Augustson, Bradley .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S423-S424

[38] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) [J].

Weisel, K. ;

Richardson, P. G. ;

Trudel, S. ;

Callander, N. ;

Nooka, A. ;

Song, K. ;

Uttervall, K. ;

Minnema, M. C. ;

Rodriguez-Otero, P. ;

Struemper, H. ;

Yeakey, A. ;

de Oca, Montes R. ;

Smith, L. M. ;

Jackson, N. ;

Kaisermann, M. ;

Im, E. ;

Basile, F. G. ;

Ahlers, C. M. ;

Holkova, B. ;

Gupta, I ;

Kremer, B. E. ;

Quach, H. .

ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 :204-205

[39] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study. [J].

Suvannasankha, Attaya ;

Bahlis, Nizar J. ;

Trudel, Suzanne ;

Weisel, Katja ;

Koenecke, Christian ;

Rocafiguera, Albert Oriol ;

Voorhees, Peter M. ;

Alonso, Aranzazu Alonso ;

Callander, Natalie Scott ;

Mateos, Maria-Victoria ;

Reddy, Nishitha ;

Hakim, Shawn ;

Patel, Nashita ;

Williams, Danae ;

Jewell, Roxanne C. ;

Zhou, Xiangdong ;

Gupta, Ira V. ;

Nooka, Ajay K. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[40] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies [J].

Weisel, K. ;

Lonial, S. ;

Lee, H. ;

Badros, A. ;

Trudel, S. ;

Nooka, A. ;

Chari, A. ;

Abdallah, A-O ;

Callander, N. ;

Sborov, D. ;

Suvannasankha, A. ;

Vorhees, P. ;

Opalinska, J. ;

Hoos, A. ;

Zhi, E. ;

Baron, J. ;

Piontek, T. ;

Jewell, R. ;

Gupta, I ;

Cohen, A. .

ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) :109-110

← 1 2 3 4 5 →